Group 1 - *ST San Sheng (002742.SZ): The controlling shareholder Pan Xianwen's 32.2 million shares have been transferred, accounting for 7.30% of the total share capital, reducing his holding from 17.26% to 16.75, with no change in company control [1] - Aikang Co., Ltd. (300889.SZ): Shareholders Zhang Fengbin and Feng Renrong reduced their holdings by a total of 1.76 million shares, accounting for 1.06% of the total share capital, completing the reduction plan [1] - Allianz Ruishi (301042.SZ): Director Shen Lei reduced his holdings by 98,700 shares, accounting for 0.14% of the total share capital, with the reduction plan period ending [1] Group 2 - Baotong Technology (300031.SZ): Controlling shareholder Bao Zhifang and director Tang Yu plan to reduce their holdings by up to 8.3749 million shares and 1.526988 million shares, accounting for no more than 2% and 0.36% of the total share capital, respectively [2] - Biyiwei (688045.SH): Shareholders Fang Guang Erqi and Yuan Chengjun plan to reduce their holdings by up to 139,680 shares and 69,840 shares, accounting for no more than 2% and 1% of the total share capital, respectively [2] - Chahua Co., Ltd. (603615.SH): Shareholder Shenzhen Hanjinliang reduced 2.397 million shares, accounting for 0.99% of the total share capital, completing the reduction plan [2] Group 3 - Dacai Co., Ltd. (605287.SH): Shareholder Qingdao Dikuang Chanquan Development Co., Ltd. reduced 3.64 million shares, accounting for 2.60% of the total share capital, completing the reduction plan [3] - Dize Pharmaceutical (688192.SH): Vice President Zhang Shiying reduced 161,550 shares, accounting for 0.0035% of the total share capital, completing the reduction plan [3] - Fuhan Micro (300613.SZ): Controlling shareholder's concerted action party plans to reduce up to 6.90208 million shares, accounting for 3% of the total share capital [3] Group 4 - Guanghuan Xinwang (300383.SZ): Directors and vice presidents plan to reduce a total of up to 720,476 shares, accounting for no more than 0.04% of the total share capital [4] - Hanyu Group (300403.SZ): Director and Vice President Wu Geming plans to reduce up to 1 million shares, accounting for 0.1658% of the total share capital [4] - Haosen Intelligent (688529.SH): Shareholders plan to reduce a total of up to 3 million shares, accounting for 1.7838% of the total share capital [4] Group 5 - Huilong New Materials (301057.SZ): Controlling shareholder's concerted action party plans to reduce up to 3.482902 million shares, accounting for 3% of the total share capital excluding repurchased shares [5] - Huitong Co., Ltd. (688219.SH): Shareholder Tong'an Fund reduced 4.667815 million shares, accounting for 0.93% of the total share capital, completing the reduction plan [5] Group 6 - Jiangsu Shentong (002438.SZ): Shareholder Huzhou Fenglin Huoshan Equity Investment Partnership reduced a total of 14.205 million shares, accounting for 2.798808% of the total share capital, completing the reduction plan [6] - Jiangtian Chemical (300927.SZ): Shareholder Jiangshan Co., Ltd. reduced 1.3265 million shares, accounting for 0.92% of the total share capital [6] - Jin Sanjiang (301059.SZ): Shareholder Guangzhou Saina reduced 104,900 shares, accounting for 0.05% of the total share capital, completing the reduction plan [6] Group 7 - Jingxue Energy (301010.SZ): Controlling shareholder's concerted action party reduced 1.08 million shares, accounting for 1% of the total share capital, completing the reduction plan [7] - Jiuwu High-Tech (300631.SZ): Vice President Wang Xiaohu and Cheng Junjun plan to reduce up to 18,900 shares and 5,000 shares, accounting for no more than 0.1511% and 0.04% of the total share capital, respectively [7] - Kanghui Pharmaceutical (603139.SH): Shareholder Shanghai Sailoxian plans to reduce up to 2.9964 million shares, accounting for 3% of the total share capital [7] Group 8 - Meino Biological (301156.SZ): Shareholder's concerted action party reduced 1.297029 million shares, accounting for 0.92% of the total share capital, completing the reduction plan [8] - Minfa Aluminum Industry (002578.SZ): Shareholder Huang Tianhuo reduced 6.6702 million shares, accounting for 0.71% of the total share capital, reducing his holding to 4.9963% [8] - Nuo Puxin (002215.SZ): Directors and senior management plan to reduce a total of up to 1.8607 million shares, accounting for no more than 0.185% of the total share capital [8] Group 9 - Entropy Technology (301330.SZ): Shareholders reduced a total of 4,693,864 shares, accounting for 1.9556% of the total share capital, completing the reduction plan [9] - Shengbang Co., Ltd. (301233.SZ): Supervisor Hu Jilin plans to reduce up to 5,650 shares, accounting for 0.0111% of the total share capital [9] - Shudao Equipment (300540.SZ): Senior management did not reduce their shares, and the reduction plan period has ended [9] Group 10 - Tongyu Communications (002792.SZ): Controlling shareholder and actual controller Shi Guiqing plans to reduce up to 15,653,487 shares, accounting for 2.9963% of the total share capital [10] Group 11 - Wuzhou Xinchun (603667.SH): Senior management plans to reduce a total of up to 22,500 shares, accounting for no more than 0.0061%, 0.0067%, and 0.0037% of the total share capital [11] - New Sharp Co., Ltd. (688257.SH): Senior management plans to reduce up to 750,000 shares, accounting for no more than 0.2971% of the total share capital [11] - New Hope (000876.SZ): Senior management reduced 225,000 shares, accounting for 0.005% of the total share capital, completing the reduction plan [11] Group 12 - Youke De (688158.SH): Shareholder Zhongyi Capital reduced 882,766 shares, accounting for 0.19% of the total share capital, completing the reduction plan [12] - Changqing Technology (001324.SZ): Shareholders reduced a total of 4,165,050 shares, accounting for 3.00% of the total share capital, completing the reduction plan [12] - Changxin Bochuang (300548.SZ): Shareholders plan to reduce up to 8.6 million shares, accounting for 2.95% of the total share capital [12] Group 13 - Zhongfu Industrial (600595.SH): Shareholder Henan Yicheng Chuangtou plans to reduce up to 40 million shares, accounting for 1% of the total share capital [13] - Zhuhai Ming Technology (300232.SZ): Controlling shareholder Lin Mingfeng plans to reduce up to 21,722,009 shares, accounting for 1.99% of the total share capital [13] - Zhuoyi Information (688258.SH): Employee shareholding platform plans to reduce up to 2,271,445 shares, accounting for no more than 1.88% of the total share capital [13]

减持股份计划期限届满暨实施结果的公告 证券代码：301156 证券简称：美农生物 公告编号：2025-042 上海美农生物科技股份有限公司 关于持股 5%以上股东的一致行动人 公司股东唐旭保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 上海美农生物科技股份有限公司（以下简称"公司"）于 2025 年 3 月 14 日 披露了《关于持股 5%以上股东的一致行动人减持股份计划的预披露公告》（公告 编号：2025-010），公司持股 5%以上股东唐凌的一致行动人唐旭计划自减持计划 预披露公告披露之日起 15 个交易日后的 3 个月内以集中竞价和大宗交易方式合 计减持其持有的公司股份不超过 1,407,846 股（即不超过公司总股本的 1%）。 公司近日收到唐旭出具的《关于持有上海美农生物科技股份有限公司股份减 持计划期限届满暨实施结果的告知函》，获悉唐旭通过集中竞价方式累计减持公 司股份 1,297,029 股，占公司总股本的 0.92%。本次减持计划实施完毕。 根据《中华人民共和国证券法》《深圳证券交易所上市 ...

Core Viewpoint - Shanghai Meino Biological Technology Co., Ltd. is undergoing a review of its stock incentive plan to ensure compliance with relevant regulations and to protect the interests of shareholders [1][2][3]. Compliance with Listing Company Requirements - The financial report for the most recent accounting year did not receive a negative opinion or inability to express an opinion from the registered accountant [1]. - There have been no instances in the last 36 months where profit distribution did not comply with laws, regulations, or company articles [1]. Compliance of Incentive Objects - The incentive plan does not include shareholders or actual controllers holding more than 5% of the company's shares [1]. - No significant violations leading to administrative penalties from the China Securities Regulatory Commission (CSRC) have occurred in the last 12 months [1]. Compliance of Incentive Plan - The total number of shares involved in all effective stock incentive plans does not exceed 20% of the company's total equity [1]. - The reserved rights for incentive objects do not exceed 20% of the proposed rights to be granted in this stock incentive plan [1]. Disclosure Completeness of Incentive Plan - The plan's purpose, criteria for determining incentive objects, and the range of those objects have been clearly stated [1]. - The number of rights to be granted and their percentage of the company's total equity have been disclosed, including any reserved rights [1]. - The plan includes details on the effective period, authorization date, and lock-up arrangements [1]. Performance Assessment Indicators - Performance assessment indicators are objective, public, clear, and beneficial for enhancing the company's competitiveness [4]. - At least three comparable companies from the same industry have been selected for benchmarking [4]. Compliance of Lock-up and Vesting Periods - The interval between the authorization date of restricted stock and the first lifting of restrictions is not less than one year [4]. - The proportion of stock options that can be exercised in each period does not exceed 50% of the total stock options granted to the incentive objects [4]. Professional Opinions and Legal Compliance - The remuneration and assessment committee has provided opinions on whether the stock incentive plan benefits the company's sustainable development [4]. - The company has engaged a law firm to issue a legal opinion in accordance with the Stock Incentive Management Measures [4].

Group 1 - The company held its 12th meeting of the 5th Board of Directors on July 3, 2025, with all 7 directors present, ensuring compliance with relevant laws and regulations [1] - The Board approved the draft of the 2025 Restricted Stock Incentive Plan to attract and retain talent while aligning the interests of shareholders, the company, and employees [1][2] - The plan aims to establish a long-term incentive mechanism and requires approval from the shareholders' meeting with a two-thirds majority [2][3] Group 2 - The Board also approved the implementation assessment management measures for the 2025 Restricted Stock Incentive Plan, which will be disclosed on the same day [2][3] - The Board proposed to authorize itself to handle various matters related to the implementation of the incentive plan, including determining eligibility and adjusting stock grants [4][5] - A temporary shareholders' meeting is scheduled for July 22, 2025, to further discuss the incentive plan [6]

Core Viewpoint - The Shanghai Meino Biological Technology Co., Ltd. has proposed a restricted stock incentive plan for 2025, which has been reviewed and deemed eligible for implementation by the Board of Directors' Compensation and Assessment Committee [1][3]. Group 1: Eligibility and Compliance - The company meets the qualifications to implement the stock incentive plan as there have been no negative or unqualified audit opinions on the financial reports for the last accounting year [1]. - The incentive plan does not include independent directors, and all selected incentive objects comply with the conditions set forth in the relevant regulations [2]. Group 2: Disclosure and Approval Process - The company is required to publicly disclose the names and positions of the incentive objects for at least 10 days prior to the shareholders' meeting [3]. - The plan's details, including grant arrangements and conditions, must be reviewed and approved by the shareholders' meeting before implementation [3]. Group 3: Objectives and Benefits - The incentive plan aims to align the interests of employees and shareholders, enhance management efficiency, and support the sustainable development of the company [3].

Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 22, 2025, at 14:30 [1] - The meeting will include both on-site voting and online voting options [2] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system on the same day [2] Voting Procedures - Shareholders can attend the meeting in person or authorize a representative to attend [2] - Voting rights can be exercised either through on-site or online voting, but not both for the same proposal [2][3] - The voting results will be based on the first valid vote in case of duplicate voting [2][3] Agenda Items - The meeting will discuss several proposals, including the "2025 Restricted Stock Incentive Plan (Draft)" and its management measures [3] - These proposals require a two-thirds majority approval from the attending shareholders [3][4] Registration Details - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [4][5] - Registration can also be done via mail or fax for remote shareholders, but must be completed by July 21, 2025 [5] Contact Information - For inquiries, shareholders can contact the company via phone, fax, or email [5][6]

Core Viewpoint - The legal opinion from Beijing Tianyuan Law Firm confirms that Shanghai Meinong Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, adhering to relevant laws and regulations [1][2][4]. Group 1: Eligibility for Stock Incentive Plan - Shanghai Meinong Biotechnology has met the conditions for implementing a stock incentive plan as per the Management Measures [2][4]. - The company is a legally established and effectively existing joint-stock company, with no circumstances that would prevent it from implementing the stock incentive plan [3][4]. Group 2: Legality and Compliance of the Incentive Plan - The incentive plan has been reviewed and found to comply with the relevant provisions of the Management Measures and Listing Rules [5][8]. - The plan includes specific provisions regarding the types, sources, and quantities of restricted stock, which align with regulatory requirements [6][7]. Group 3: Legal Procedures Followed - The company has followed the necessary legal procedures, including meetings of the independent directors and the remuneration and assessment committee, to approve the incentive plan [8][10]. - The company will disclose the names and positions of the incentive plan participants prior to the shareholders' meeting, ensuring transparency [9][11]. Group 4: Financial Support and Impact on Shareholders - The company has committed not to provide any financial assistance to the incentive plan participants for acquiring restricted stock, in compliance with regulations [12]. - The incentive plan is not expected to harm the interests of the company or its shareholders, as confirmed by the remuneration and assessment committee [12][13]. Group 5: Conclusion - The legal opinion concludes that the incentive plan is compliant with the Management Measures and requires approval from the shareholders' meeting to be implemented [14].

北京市天元律师事务所 关于上海美农生物科技股份有限公司 2025 年限制性股票激励计划的法律意见 京天股字（2025）第 460 号 致：上海美农生物科技股份有限公司 北京市天元律师事务所（以下简称"本所"）接受上海美农生物科技股份有限公 司（以下简称"美农生物"、"公司"或"上市公司"）的委托，担任公司 2025 年限制性 股票激励计划（以下简称"本次股权激励计划"或"本激励计划"）的专项法律顾问， 为公司本次股权激励计划有关事宜出具本法律意见。 为出具本法律意见，本所律师审阅了公司拟定的《上海美农生物科技股份有限 公司 2025 年限制性股票激励计划（草案）》（以下简称"《激励计划》"）以及本所 律师认为需要审查的其他文件，对相关的事实和资料进行了核查和验证。本所及经 办律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、 《律师事务所从事证券法律业务管理办法》、《律师事务所证券法律业务执业规则 （试行）》等规定及本法律 ...

上海美农生物科技股份有限公司 2025 年限制性股票激励计划实施考核管理办法 上海美农生物科技股份有限公司（以下简称"公司"）为进一步完善公司法 人治理结构，建立、健全公司长效激励约束机制，形成良好均衡的价值分配体系， 吸引与留住优秀人才，充分调动公司董事、高级管理人员、营销管理者和销售骨 干、研发管理者和核心技术骨干，以及公司其他核心部门的管理者的积极性，使 其更诚信勤勉地开展工作，以促进公司业绩稳步持续提升，确保远期发展战略及 经营目标的实现，拟实施 2025 年限制性股票激励计划（以下简称"本激励计 划"）。 为保证本激励计划的顺利实施和规范运行，现根据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业 务办理》等有关法律、法规和规范性文件以及《上海美农生物科技股份有限公司 章程》、本激励计划的相关规定，并结合公司实际情况，特制定《上海美农生物 科技股份有限公司 2025 年限制性股票激励计划实施考核管理办法》（以下简称 "本办法"）。 一、考核目的 进一步完善公司现代企业法人治理 ...

证券代码：301156 证券简称：美农生物 公告编号：2025-041 上海美农生物科技股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）和《公司章程》 的规定，经上海美农生物科技股份有限公司（以下简称"公司"或"本公司"） 第五届董事会第十二次会议审议通过，公司决定于 2025 年 7 月 22 日（星期二） 召开公司 2025 年第一次临时股东会。现将会议相关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会召集人：公司董事会 3、会议召开的合法、合规性：本次股东会的召开符合《公司法》《深圳证 券交易所创业板股票上市规则》等有关法律法规、部门规章、规范性文件及《公 司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开的时间：2025 年 7 月 22 日（星期二）14:30； （2）网络投票时间：2025 年 7 月 22 日（星期二）； 其中，通过深圳证券交易所（以下简称"深交所"）交易 ...